全文获取类型
收费全文 | 835篇 |
免费 | 14篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 8篇 |
妇产科学 | 12篇 |
基础医学 | 38篇 |
口腔科学 | 5篇 |
临床医学 | 36篇 |
内科学 | 44篇 |
皮肤病学 | 1篇 |
神经病学 | 256篇 |
特种医学 | 2篇 |
外科学 | 14篇 |
综合类 | 29篇 |
预防医学 | 31篇 |
眼科学 | 1篇 |
药学 | 366篇 |
中国医学 | 5篇 |
肿瘤学 | 2篇 |
出版年
2023年 | 9篇 |
2022年 | 11篇 |
2021年 | 24篇 |
2020年 | 21篇 |
2019年 | 12篇 |
2018年 | 20篇 |
2017年 | 20篇 |
2016年 | 24篇 |
2015年 | 19篇 |
2014年 | 22篇 |
2013年 | 73篇 |
2012年 | 29篇 |
2011年 | 44篇 |
2010年 | 30篇 |
2009年 | 46篇 |
2008年 | 38篇 |
2007年 | 34篇 |
2006年 | 28篇 |
2005年 | 28篇 |
2004年 | 19篇 |
2003年 | 10篇 |
2002年 | 14篇 |
2001年 | 7篇 |
2000年 | 6篇 |
1999年 | 13篇 |
1998年 | 4篇 |
1997年 | 9篇 |
1996年 | 12篇 |
1995年 | 16篇 |
1994年 | 8篇 |
1993年 | 10篇 |
1992年 | 10篇 |
1991年 | 10篇 |
1990年 | 12篇 |
1989年 | 13篇 |
1988年 | 5篇 |
1987年 | 10篇 |
1986年 | 8篇 |
1985年 | 19篇 |
1984年 | 19篇 |
1983年 | 6篇 |
1982年 | 9篇 |
1981年 | 10篇 |
1980年 | 15篇 |
1979年 | 9篇 |
1978年 | 5篇 |
1977年 | 5篇 |
1974年 | 8篇 |
1972年 | 5篇 |
1970年 | 4篇 |
排序方式: 共有850条查询结果,搜索用时 15 毫秒
1.
2.
抗抑郁治疗对功能性消化不良的辅助治疗作用 总被引:6,自引:0,他引:6
功能性消化不良是指具有上腹痛、上腹胀,早饱、暖气、食欲不振、恶心、呕吐等上腹不适症状,经检查排除引起这些症状的器质性疾病的一组临床综合征。在经济、科技、工业化高度发展的社会,已经成为危害人们健康状况和生活质量的最常见的消化系统疾病,因而受到广泛重视。欧美的流行病学调查表明,普通人群中有消化不良症状者占19%-41%,在我国人群中总的患病率为20%。普通门诊中占20%-40%,在消化专科中占60%-70%。FD的发病机制复杂,部分患者存在精神心理的异常,本文通过对FD患者进行抑郁自评量表(zuag评分)评定和抗抑郁药物治疗,旨在探讨二者关系及抗抑郁治疗FD的疗效。 相似文献
3.
Alex L. van Bemmel Rutger H. van den Hoofdakker Domien G. M. Beersma Antoinette L. Bouhuys 《Psychopharmacology》1993,113(2):225-230
Drug-induced improvement of depression may be mediated by changes in sleep physiology. The aim of this study was to relate changes in sleep polygraphic variables to clinical state during treatment with citalopram, a highly specific serotonin uptake inhibitor. Sixteen patients took part. The study was single-blind and uncontrolled. A 1-week wash-out period was followed by 1 week of placebo administration, a medication period of 5 weeks, and a 1-week placebo period. For the entire group a significant decrease of rapid eye movement sleep (REMS) and a significant lengthening of REMS latency were observed initially as well as at the end of treatment. No changes in sleep continuity were found, but non-REMS stage 2 (percentage) was significantly increased. On the basis of clinical change, as expressed by the scores of the Hamilton Rating Scale for Depression, at the end of the citalopram treatment the patient group was split in two halves: eight less and eight more improved patients. The groups did not differ with respect to any sleep polygraphic varible. 相似文献
4.
Antidepressant-associated maniform states in acute treatment of patients with bipolar-I depression 总被引:2,自引:0,他引:2
R. Bottlender Daniel Rudolf Anton Strauss Hans-Jürgen Möller 《European archives of psychiatry and clinical neuroscience》1998,248(6):296-300
Medical records of 158 patients with bipolar depression were analysed for the incidence of a switch from depression to maniform
states (mania and hypomania). Relation to psychopharmacological treatment was investigated. Thirty-nine (25%) patients of
the total sample had switched to a maniform state during the treatment period in the hospital. Among that group the phenomenon
occurred in 23 patients (15%) as a hypomania and in 16 patients (10%) as a mania. Patients with a switch were significantly
more often treated with tricyclic antidepressants (TCA) than patients without switch (79.5% vs 51.3%). Mood stabilising medication
might reduce the risk for switching, especially in patients treated with TCA; however, it seems not totally sufficient, since
59% of the switched patients received mood stabilisers. The switch phenomenon was not associated with sociodemographic or
clinical data.
Received: 23 September 1998 / Accepted: 28 September 1998 相似文献
5.
Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants 总被引:16,自引:0,他引:16
This study demonstrated that distinct patterns of active behaviors are produced by antidepressants that selectively inhibit norepinephrine (NE) or serotonin (5-HT) uptake in the rat forced swimming test (FST). A behavior sampling technique was developed to score the active behaviors swimming, climbing and diving, as well as immobility. The rat's behavior was recorded at the end of each 5-s period during the test session. The sampling technique was both reliable, as demonstrated by test-retest reliability and inter-rater reliability, and valid, as shown by comparison to the timing of behavior durations. Five different antidepressant drugs which block monoamine uptake and two 5-HT1A receptor agonists were shown to decrease immobility in the FST; however, they produced distinct patterns of active behaviors. The selective NE uptake inhibitors desipramine and maprotiline selectively increased climbing, whereas the selective serotonin reuptake inhibitors (SSRIs) fluoxetine, sertraline and paroxetine selectively increased swimming. The 5-HT1A receptor agonists 8-OH-DPAT and gepirone also selectively increased swimming. These results show that:1) SSRIs are not false negatives in the FST; 2) at least two behaviorally distinct processes occur in the FST; and 3) enhancement of NE neurotransmission may mediate climbing in the FST, whereas enhancement of 5-HT neurotransmission may mediate swimming. 相似文献
6.
G. Bassotti F. Sietchiping Nzepa G. de Roberto M. J. Fischer A. Morelli 《Digestive and liver disease》2004,36(1):78-81
Selective serotonin reuptake inhibitors are frequently employed to treat depression. However, although rarely, coagulation abnormalities have been described following the use of these compounds, and these effects appear to be enhanced by simultaneous use of nonsteroidal anti-inflammatory drugs. We describe a case of reversible symptomatic duodenal compression caused by a retroperitoneal hematoma after ingestion of sertraline and nimesulide. 相似文献
7.
The effects of moclobemide, a new selective and reversible MAO-A inhibitor, on cognitive function and psychomotor performance were measured in 12 healthy elderly male volunteers (with a mean age of 72.5 years). Subjects received moclobemide 200 mg, amitriptyline (positive internal control) 25 mg or placebo twice daily and were assessed on a battery of psychometric tests on the mornings following the first (acute) day and seventh (sub-chronic) day. The tests were: Choice Reaction Time; Tracking; Critical Flicker Fusion Threshold; Memory Scanning; Continuous Attention Task; the Leeds Sleep Evaluation Questionnaire and a Visual Line Analogue Rating Scale. The results show that amitriptyline produced impairment of cognitive and psychomotor functions. Moclobemide, however, did not disrupt sleep or cause daytime sedation, and remained neutral in the assessment of behavioural toxicity. 相似文献
8.
J. Harro Charlotta Löfberg Rein Pähkla Vallo Matto Lembit Rägo Lars Oreland Lembit Allikmets 《Naunyn-Schmiedeberg's archives of pharmacology》1996,355(1):57-63
Cholecystokinin (CCK) is a neuropeptide recently implicated in affective disorders. This study aimed at measuring the levels
of different molecular forms of CCK and the binding characteristics of CCKB receptors in the rat brain after three weeks of treatment with four different antidepressants, imipramine, amitriptyline,
desipramine, and citalopram (all at the dose of 10 mg/kg once per day i.p.). Chronic treatment with imipramine and desipramine
had a significant immobility-reducing effect in the Porsolt‘s swim test. The effect of amitriptyline, albeit in the same direction,
was not significant, and citalopram had no effect in this test. In the elevated plus-maze test of anxiety, all drugs tended
to increase the number of open arm entries and the ratio open/total arm entries, but only the effects of imipramine were statistically
significant. None of the treatments affected the total levels of CCK or the levels of CCK-8-sulphated, CCK-8-nonsulphated,
CCK-5, or CCK-4 in the frontal cortex. There was no effect of the treatments on CCKB receptor binding in the frontal cortex, hippocampus, or striatum. Imipramine and amitriptyline, however, increased the affinity
of CCKB receptor binding in the hypothalamus. Thus, no consistent effect of chronic antidepressant treatment on the CCK-ergic neurotransmission
in the rats was found.
Received: 4 June 1996 / Accepted: 26 August 1996 相似文献
9.
Louis D. Van de Kar 《Neuroscience and biobehavioral reviews》1989,13(4):237-246
This review examines the role of serotonin (5-HT) in depression. Dysfunction of serotonergic neurons has been implicated as one of the causes of endogenous depression. Since serotonergic neurons innervate the hypothalamus and these neurons send collaterals to several other brain areas, it is possible that hypothalamic sites which control hormone secretion receive the same serotonergic afferents that innervate other limbic areas in the brain. Several investigators have devised neuroendocrine challenge tests measuring the effect of 5-HT agonists on plasma cortisol and prolactin in depressed patients. These tests help to identify dysfunctional 5-HT neurons, and are a "window into the brain." The secretion of cortisol and prolactin is increased predominantly by 5-HT1 receptors. However, changes in 5-HT2 receptors have also been implicated in depression. Results from our laboratory and by others suggest that brain serotonergic neurons stimulate renin and vasopressin secretion by activation of 5-HT2 receptors. Therefore, the renin and vasopressin response to 5-HT agonists should be included in neuroendocrine tests of serotonergic function in affective disorders. Since antidepressants produce a decrease in the density of 5-HT2 receptors, renin and vasopressin could be used to evaluate the antidepressant potential of new drugs. 相似文献
10.
Summary Study design: As part of a large screening study of perinatal depression, pregnant women were screened for demographic, depression and treatment variables in obstetrics clinics. Women taking antidepressant medication prior to conception were included in the sample as the study aimed to document rates of antidepressant medication use, and relationship to depressive symptomatology.Results: Among women who reported using antidepressant medications within 2 years prior to screening (n = 390, or 11% of all women), 22% reported current use of these medications. Women who reported using antidepressant medications (52%) and those who discontinued them (49%) evidenced elevated depressive symptoms during pregnancy.Conclusions: Both women who discontinue and some who continue antidepressants during pregnancy demonstrate depressive symptoms, suggesting sub-optimal management of both groups. Future studies should carefully assess the adequacy of treatments prescribed as well as the monitoring and adherence of recommended treatments. Full symptom remission should be the goal for antenatal and postnatal depression in order to minimize risk to mother and baby. 相似文献